135 related articles for article (PubMed ID: 25183236)
1. Hypoglycemic seizures and epilepsy in type I diabetes mellitus.
Falip M; Miró J; Carreño M; Jaraba S; Becerra JL; Cayuela N; Perez Maraver M; Graus F
J Neurol Sci; 2014 Nov; 346(1-2):307-9. PubMed ID: 25183236
[TBL] [Abstract][Full Text] [Related]
2. Seizures and type 1 diabetes mellitus: current state of knowledge.
Verrotti A; Scaparrotta A; Olivieri C; Chiarelli F
Eur J Endocrinol; 2012 Dec; 167(6):749-58. PubMed ID: 22956556
[TBL] [Abstract][Full Text] [Related]
3. Type 1 diabetes and epilepsy in childhood and adolescence: Do glutamic acid decarboxylase autoantibodies play a role? Data from the German/Austrian/Swiss/Luxembourgian DPV Registry.
de Sousa GJ; Tittel SR; Häusler M; Holterhus PM; Berger G; Holder M; Kamrath C; Golembowski S; Herrlinger S; Holl RW
Pediatr Diabetes; 2020 Aug; 21(5):766-773. PubMed ID: 32333480
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies.
Falip M; Carreño M; Miró J; Saiz A; Villanueva V; Quílez A; Molins A; Barceló I; Sierra A; Graus F
Eur J Neurol; 2012 Jun; 19(6):827-33. PubMed ID: 22353320
[TBL] [Abstract][Full Text] [Related]
5. High titre of antiglutamic acid decarboxylase autoantibody is a strong predictor of the development of thyroid autoimmunity in patients with type 1 diabetes and latent autoimmune diabetes in adults.
Jin P; Huang G; Lin J; Yang L; Xiang B; Zhou W; Zhou Z
Clin Endocrinol (Oxf); 2011 May; 74(5):587-92. PubMed ID: 21470281
[TBL] [Abstract][Full Text] [Related]
6. Musicogenic reflex seizures in epilepsy with glutamic acid decarbocylase antibodies.
Falip M; Rodriguez-Bel L; Castañer S; Miro J; Jaraba S; Mora J; Bas J; Carreño M
Acta Neurol Scand; 2018 Feb; 137(2):272-276. PubMed ID: 28766694
[TBL] [Abstract][Full Text] [Related]
7. Systemic and neurologic autoimmune disorders associated with seizures or epilepsy.
Vincent A; Crino PB
Epilepsia; 2011 May; 52 Suppl 3():12-7. PubMed ID: 21542840
[TBL] [Abstract][Full Text] [Related]
8. GAD-65 autoantibody associated epilepsy.
Dimova R; Grozeva G; Chakarova N; Tsarkova P; Tankova T
J Pediatr Endocrinol Metab; 2020 May; 33(6):817-820. PubMed ID: 32436860
[TBL] [Abstract][Full Text] [Related]
9. Anti glutamate-decarboxylase antibodies: a liaison between localisation related epilepsy, stiff-person syndrome and type-1 diabetes mellitus.
Szűcs A; Barcs G; Winkler G; Soós Z; Folyovich A; Kelemen A; Várallyay P; Kamondi A
Ideggyogy Sz; 2014 Jul; 67(7-8):269-71. PubMed ID: 25509368
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous triple organ specific autoantibody profiling in adult patients with type 1 diabetes mellitus and their first-degree relatives.
Dagdelen S; Hascelik G; Bayraktar M
Int J Clin Pract; 2009 Mar; 63(3):449-56. PubMed ID: 18218004
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy.
Liimatainen S; Peltola M; Sabater L; Fallah M; Kharazmi E; Haapala AM; Dastidar P; Knip M; Saiz A; Peltola J
Epilepsia; 2010 May; 51(5):760-7. PubMed ID: 19817821
[TBL] [Abstract][Full Text] [Related]
12. Type 1 diabetes mellitus in people with pharmacoresistant epilepsy: Prevalence and clinical characteristics.
Keezer MR; Novy J; Sander JW
Epilepsy Res; 2015 Sep; 115():55-7. PubMed ID: 26220376
[TBL] [Abstract][Full Text] [Related]
13. Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications.
Lilleker JB; Biswas V; Mohanraj R
Seizure; 2014 Sep; 23(8):598-602. PubMed ID: 24836709
[TBL] [Abstract][Full Text] [Related]
14. Association between high titers of glutamic acid decarboxylase antibody and epilepsy in patients with type 1 diabetes mellitus: A cross-sectional study.
Aguiar TS; Dantas JR; Cabral DB; Rêgo CCS; Zajdenverg L; Salles GF; Alves-Leon SV; Rodacki M; Lima MA
Seizure; 2019 Oct; 71():318-321. PubMed ID: 31525611
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of neural antibodies in temporal lobe epilepsy and the clinical characteristics of seropositive patients.
Elisak M; Krysl D; Hanzalova J; Volna K; Bien CG; Leypoldt F; Marusic P
Seizure; 2018 Dec; 63():1-6. PubMed ID: 30391660
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: A study on 233 patients.
Errichiello L; Perruolo G; Pascarella A; Formisano P; Minetti C; Striano S; Zara F; Striano P
J Neuroimmunol; 2009 Jun; 211(1-2):120-3. PubMed ID: 19428124
[TBL] [Abstract][Full Text] [Related]
17. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies.
Malter MP; Frisch C; Zeitler H; Surges R; Urbach H; Helmstaedter C; Elger CE; Bien CG
Seizure; 2015 Aug; 30():57-63. PubMed ID: 26216686
[TBL] [Abstract][Full Text] [Related]
18. Gender differences in GAD antibody-positive diabetes mellitus in relation to age at onset, C-peptide and other endocrine autoimmune diseases.
Lindholm E; Hallengren B; Agardh CD
Diabetes Metab Res Rev; 2004; 20(2):158-64. PubMed ID: 15037992
[TBL] [Abstract][Full Text] [Related]
19. Glutamic acid decarboxylase antibodies in idiopathic generalized epilepsy and type 1 diabetes.
Striano P; Perruolo G; Errichiello L; Formisano P; Beguinot F; Zara F; Striano S
Ann Neurol; 2008 Jan; 63(1):127-8. PubMed ID: 17167787
[No Abstract] [Full Text] [Related]
20. Heterogeneity among patients with latent autoimmune diabetes in adults.
Maruyama T; Nakagawa T; Kasuga A; Murata M
Diabetes Metab Res Rev; 2011 Nov; 27(8):971-4. PubMed ID: 22069295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
